{"analyses":[{"ciLowerLimit":"0.26","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","groupDescription":"Physical Functioning: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0035","paramType":"Hazard Ratio (HR)","paramValue":"0.45","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.23","groupDescription":"Role Functioning: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2214","paramType":"Hazard Ratio (HR)","paramValue":"0.71","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.88","groupDescription":"GHS/QoL: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0135","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"2.10","upperLimit":"NA","value":"5.62"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"9.69","upperLimit":"NA","value":"13.14"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"2.14","upperLimit":"NA","value":"NA"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"7.20","upperLimit":"NA","value":"NA"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.48","upperLimit":"9.82","value":"3.58"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"6.24","upperLimit":"NA","value":"9.76"}]}],"title":"GHS/QoL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"TTD was defined as the time from randomization to the first deterioration (decrease from baseline of \\>/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - China"},{"description":"Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - China"}],"paramType":"MEDIAN","populationDescription":"China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"Time to Deterioration (TTD) in the China Population","type":"SECONDARY","unitOfMeasure":"months"}